|
|
|
|
|
Dactinomycin
drug data and news
Dactinomycin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Dactinomycin | ||
| Brand Names/Synonyms | -Pentone; A1410; ACT; ACT D; ACTINOMYCIN D; ACTO-D; AD; Actactinomycin a Iv; Actinomycin 11 Cosmegen; Actinomycin 7; Actinomycin Aiv; Actinomycin C1; Actinomycin D; Actinomycin I; Actinomycin I1; Actinomycin Iv; Actinomycin X 1; Actinomycindioic D Acid, D | ||
| Indication | For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis. | ||
| Mechanism Of Action | Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. | ||
| Dactinomycin News (When available) |
Sudden Hike In Cancer Drug's Price Surprises Families May 1, 2006 | ||
| Dosage Forms | Injectable and parenteral solution | ||
| Drug_Category | Antibiotics; Anti-bacterial Agents; Antineoplastic Agents; ATC:L01DA01 | ||
| Absorption | poorly absorbed from gastrointestinal tract | ||
| Interactions |
-->Interactions for Dactinomycin: Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels. | ||
| Toxicity | hepatoxicity | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 8-amino-N-(2-amino-4,6-dimethyl-3-oxo-phenoxazin-1-yl)carbonyl-N'-[8-amino-4,6-dimethyl-7-oxo-9-[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]carbamoyl]phenoxazin-1-yl]carbonyl-4,6-dimethyl-7-oxo-N,N'-bis[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]-1,9-bis[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]carbamoyl]phenoxazine-1,9-dicarboxamide | ||
| Chemical Formula | C62H86N12O16 | ||
| Molecular Weight | 1255.42 g/mol | ||
| Smiles String | CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C | ||
| Melting Point | 241.5 - 243 °C | ||
| Water Solubility | Soluble at 10 C | ||
| State | solid | ||
| LogP/Hphobicity | 0.517 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | hepatic | ||
| Half Life | 36 hours | ||
| Protein Binding [%] | 5% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Dactinomycin.html http://www.rxlist.com/cgi/generic2/dactinomycin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00124 | ||
| CAS Registry Number | 50-76-0 | ||
| KEGG Compound ID | C06770 | ||
| PubChem ID | SID:8990 | ||
| PharmGKB ID | PA449199 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 213071 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |